Kissinger Patricia, Secor W Evan, Leichliter Jami S, Clark Rebecca A, Schmidt Norine, Curtin Erink, Martin David H
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Clin Infect Dis. 2008 Apr 1;46(7):994-9. doi: 10.1086/529149.
The purpose of the study was to examine whether early repeated infections due to Trichomonas vaginalis among human immunuodeficiency virus (HIV)-positive and HIV-negative women are reinfections, new infections, or cases of treatment failure.
Women attending an HIV outpatient clinic and a family planning clinic in New Orleans, Louisiana, who had culture results positive for T. vaginalis were treated with 2 g of metronidazole under directly observed therapy. At 1 month, detailed sexual exposure and sexual partner treatment information was collected. Isolates from women who had clinical resistance (i.e., who tested positive for a third time after treatment at a higher dose) were tested for metronidazole susceptibility in vitro.
Of 60 HIV-positive women with trichomoniasis, 11 (18.3%) were T. vaginalis positive 1 month after treatment. The 11 recurrences were classified as 3 probable reinfections (27%), 2 probable infections from a new sexual partner (18%), and 6 probable treatment failures (55%); 2 of the 6 patients who experienced probable treatment failure had isolates with mild resistance to metronidazole. Of 301 HIV-negative women, 24 (8.0%) were T. vaginalis positive 1 month after treatment. The 24 recurrences were classified as 2 probable reinfections (8%) and 22 probable treatment failures (92%); of the 22 patients who experienced probable treatment failure, 2 had strains with moderate resistance to metronidazole, and 1 had a strain with mild resistance to metronidazole.
HIV-positive women were more likely to have sexual re-exposure than were HIV-negative women, although the rate of treatment failure was similar in both groups. High rates of treatment failure among both HIV-positive and HIV-negative women indicate that a 2-g dose of metronidazole may not be adequate for treatment of some women and that rescreening should be considered.
本研究的目的是调查人类免疫缺陷病毒(HIV)阳性和HIV阴性女性中由阴道毛滴虫引起的早期反复感染是再感染、新感染还是治疗失败病例。
在路易斯安那州新奥尔良市的一家HIV门诊和一家计划生育诊所就诊、阴道毛滴虫培养结果呈阳性的女性,在直接观察治疗下接受2克甲硝唑治疗。在1个月时,收集详细的性接触和性伴侣治疗信息。对临床耐药(即在高剂量治疗后第三次检测仍呈阳性)女性的分离株进行甲硝唑体外敏感性检测。
60例患滴虫病的HIV阳性女性中,11例(18.3%)在治疗1个月后阴道毛滴虫检测仍呈阳性。这11例复发病例分类如下:3例可能为再感染(27%),2例可能为来自新性伴侣的感染(18%),6例可能为治疗失败(55%);6例可能治疗失败的患者中有2例的分离株对甲硝唑有轻度耐药。301例HIV阴性女性中,24例(8.0%)在治疗1个月后阴道毛滴虫检测呈阳性。这24例复发病例分类如下:2例可能为再感染(8%),22例可能为治疗失败(92%);22例可能治疗失败的患者中,2例菌株对甲硝唑有中度耐药,1例菌株对甲硝唑有轻度耐药。
HIV阳性女性比HIV阴性女性更易发生性再接触,尽管两组的治疗失败率相似。HIV阳性和HIV阴性女性的高治疗失败率表明,2克剂量的甲硝唑可能不足以治疗某些女性,应考虑重新筛查。